EUVIMEDEUVIMED entdecken
Open Access

For-Profit Dialysis and Academic Neglect Are Undermining Dialysis Research in the United States

Josephine P Briggs iD, Thomas H Hostetter iD

Journal of the American Society of Nephrology · 2026-10 · 37 (10) · 2322-2324

DOI: 10.1681/asn.0000001128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 20.04.2026. Verfasst von Josephine P Briggs und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan, Ann Arbor, Michigan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

If the treatment of chronic uremia cannot fully rehabilitate the patient, the treatment is inadequate. —Belding Scribner Dialysis Is Lifesaving for People with Failed Kidneys Fifty-three years ago, faced with death panels rationing care and impressed by the ground-breaking demonstration that dialysis could keep people with kidney failure alive, Congress passed the Social Security Act of 1972. It provided Medicare coverage for people with kidney failure, assuming most costs of dialysis. This was a spectacular victory for access to care. Nonetheless proponents did not anticipate the magnitude of needs and costs or the subsequent dominance by for-profit care. Now, 53 years later, half a million Americans, 480,000 at the last count, receive in-center hemodialysis.1 A success, but current dialysis care exemplifies many of the problems of for-profit corporatized health care.2–4 Dialysis Does Not Fully Rehabilitate Many aspects of dialysis are unchanged from the methods pioneered by Willem Kolff and Belding Scribner more than 50 years ago. Although devices have evolved and management of renal anemia has dramatically improved, patient experience is largely unchanged. Three times a week in-center hemodialysis remains a grim treatment. It leaves patients with debilitating fatigue, reduced quality of life, and markedly shortened life expectancy. Most dialysis patients are unable to return to full-time employment. Median life expectancy on dialysis is only 3–5 years, and modest improvement in life expectancy has stalled.1,5 Care of Patients with Failed Kidneys Is Expensive Total Medicare cost for people with kidney failure is currently $55 billion, about one third of which is the direct costs of dialysis treatments. Each patient receiving fee-for-service care costs Medicare close to $100,000 per year.1 Dialysis Care Is Highly Consolidated, with Limited Competition Currently, most dialysis care is provided by two publicly traded companies, Fresenius Medical Care and DaVita, commonly called large dialysis organizations (LDOs). They operate 5000 dialysis facilities across the United States and provide approximately 80% of dialysis.1 Corporate investments have helped meet the enormous challenge of delivering care to half a million people three times a week, delivering largely safe and guideline-adherent care. Industry investments have made important contributions to patient safety and to overcome staffing challenges. Nevertheless, major concerns exist,6 with similar problems seen with corporatization in other settings.2–4 The standardized care provided in for-profit dialysis facilities does not consistently meet individual patient's needs. It does not reduce public costs. Market forces operate poorly in a dialysis setting because proximity to home drives facility selection. Corporate dialysis contributes to increased professional dissatisfaction among nephrologists, nurses, and technicians and the difficulty in recruiting professionals to the field.7 We share these concerns. In this Perspective, however, we focus on the effect of corporatization on research and innovation, drawing on our own experience from decades in government and academia and from a series of informal conversations with colleagues currently active in dialysis trials. We asked a series of questions. Is the Shortage of Dialysis Trials due to the Lack of Pressing Research Questions? The answer to this question was an emphatic “no.” We heard of many promising ideas. Innovative dialysis instrumentation—e.g., with artificial intelligence (AI) tools—could improve volume management and avoidance of intradialytic hypotension. We were told of promising pharmaceutical approaches to management of dialysis-related symptoms such as painful leg cramps and the prolonged postsession fatigue. New insights into kidney–heart connections is generating testable hypotheses.8 Studies on hemodiafiltration performed outside the United States have raised interest in this approach to improve outcomes,9 but replication is critical. Researchable questions also abound about the practical steps for implementation of hemodiafiltration in the US delivery environment. Research is needed to develop algorithms for conservative care and individualized treatment, e.g., for incremental dialysis to preserve residual kidney function or to promote recovery of AKI. Does the Current Organization of Dialysis Care or Its Reimbursement Impede Research? The highly structured care provided to dialysis patients should provide an ideal setting for clinical research. Patients typically spend 12 hours per week in facilities and develop strong ties to care personnel, reducing the usual trial hurdles of patient identification, recruitment, and retention. With appropriate ethical review, many questions can be addressed by site randomization. Information systems are generally strong. But, in the United States, it has not worked well. Facilities owned by both chains are participating in some current publicly funded trials and have contributed sites to previous trials of critical issues such as nocturnal home dialysis, access management, duration of treatment, and phosphate management, but the industry contribution has been modest and has not alleviated the intense constraints on public sector funding. Trials have been slow and often underpowered. Two major trials were stopped because of failure to achieve separation between arms (TIME and HiLO), reflecting in part, at least, lukewarm and uneven LDO support. With current reimbursement policies, dialysis regimens that vary from the standard of several hours thrice-weekly leave dialysis chairs empty or alter staffing needs and are seen as barriers to profitability. Trialists noted that even modest commitments of staff time are viewed as too much. The legalistic red tape required by the LDOs is onerous and time consuming. Major trials of dialysis are largely happening outside the United States. Important trials in Australia, Canada, and Europe, such as CONVINCE and PISCES, have shown significant improvements in cardiovascular disease and mortality.9,10 RESOLVE, a major ongoing international pragmatic trial to test the optimum NaCl concentration in dialysate, is on track to recruit 50,000 patients. Efforts to establish participation of US sites has not been successful. Pharmaceutical and device investment has lagged, at least in the United States, and LDO–pharma partnerships are rare. In 1983, to control ballooning costs, Medicare established a composite dialysis per-treatment rate, the bundle, later expanded to include dialysis drugs. Several of our discussants attribute the stagnant state of dialysis research to the effect of the bundle on financial incentives. Steps taken by Centers for Medicare & Medicaid Services to improve incentives include establishment of programs that create windows for reimbursement of approved drugs and devices. Some success is attributed to these programs, but the effect has been limited. For example, use of a calcimimetic declined abruptly after the window of reimbursement ended, leading to documented worsening of secondary hyperparathroidism.11 The rapid growth in participation in Medicare Advantage insurance, actively promoted by the LDOs, has led to increased costs to the taxpayer, but has not improved outcomes. The recurrent theme in our conversations with researchers was that, despite statements to the contrary, LDOs prioritize profitability, and that research in LDO facilities is generally only possible if it will predictably serve corporate interests, severely limiting the range of questions. What Role Has Academic Nephrology Played? The academic community, of which we are senior members, shares substantial responsibility for the problems described above. As academic leaders, we all have intertwined ethical responsibilities: for the patients in our care, for the trainees enrolled in our programs, and for the research programs we lead. Referral to outpatient dialysis from an academic nephrology division is typically accompanied by complete deference to the protocolized care of the facility. The patient becomes their patient, not ours. Contractual relationships of academic units with LDOs, often financially advantageous, nonetheless undermine ethical responsibilities to patients and to trainees. Trainees and faculty, with important exceptions, are not embedded in dialysis care in a way that drives clinical decisions. The lack of active clinical participation hinders the identification of decisional dilemmas and the refinement of research questions. The second-class status of dialysis care and research is long-standing. Historically, nephrology research focused on physiology, i.e., learn how the kidney works. Prominent voices in nephrology argued for research to shift to an emphasis on mechanisms of disease and slowing of progression, valuable developments that are currently bearing fruit with new treatments and with promise for porcine transplantation. These advances portend improved care for patients. All this news is heartening, but the good news should not distract us from the unsolved problems in the care of dialysis patients. Better treatments will, we believe, over time result in fewer patients with failed kidneys. Nevertheless, for the foreseeable future, the need for dialysis will persist, and care of dialysis patients will continue to be one of the main activities of the practicing nephrologist. Change is needed. Some of the practical suggestions we have heard are outlined in Table 1. Table 1 - Examples of steps to improve care of dialysis patients Who? What? Academic nephrology • Pay more attention to dialysis care • Ensure academic credit is given to dialysis research • Review institutional contractual arrangements and medical director agreements to ensure professional autonomy • Ensure partnering dialysis facilities provide training environments with appropriate clinical responsibility for trainees • Ensure facility formularies include optimum options for patients Federal payers, federal and state regulators • Ensure transparency of Medicare advantage data through USRDS • Strengthen antitrust oversight at state and federal levels • Establish incentive structures that do not hinder incremental dialysis when clinically indicated Large dialysis organizations • Recognize patients as stakeholders • Do more to promote and financially support research • Reduce procedural and legalistic red tape for research studies • Strengthen partnerships with academic nephrologists USRDS, United States Renal Data System. Optimizing Dialysis Care Remains a Moral Responsibility of Our Discipline The domination of dialysis care by two for-profit LODs has led to standardized one-size-fits-all care, which promotes profitability but has a chilling effect. It leaves little room for optimizing individual care and makes incorporating research challenging or impossible. Federal reimbursement policy, despite attempts to create windows for innovation, has devolved into a tug-of war between payers and dialysis organizations. It has failed to foster active research involvement and a climate of care improvement. Academic nephrologists are complicit in these developments. We have largely accepted the protocolized care provided by large dialysis organizations, ceding responsibility for patient management and assigning second class status to dialysis care and research.

Schlagwörter

Stichwörter der Autor:innen

clinical sciencedialysiseconomic impacthealth policy

Autor:innen und Institutionen

  • University of Michigan, Ann Arbor, Michigan.
  • University of North Carolina, Chapel Hill, North Carolina.

ORCID-Profile: Josephine P Briggs, Thomas H Hostetter

Zitieren

APA

Briggs, J. P., & Hostetter, T. H. (2026). For-Profit Dialysis and Academic Neglect Are Undermining Dialysis Research in the United States. Journal of the American Society of Nephrology, 37(10), 2322-2324. https://doi.org/10.1681/asn.0000001128

Vancouver

Briggs JP, Hostetter TH. For-Profit Dialysis and Academic Neglect Are Undermining Dialysis Research in the United States. Journal of the American Society of Nephrology. 2026;37(10):2322-2324. doi:10.1681/asn.0000001128

BibTeX
@article{Briggs2026,
  author = {Briggs, Josephine P and Hostetter, Thomas H},
  title = {For-Profit Dialysis and Academic Neglect Are Undermining Dialysis Research in the United States},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  volume = {37},
  number = {10},
  pages = {2322--2324},
  doi = {10.1681/asn.0000001128}
}
Kostenlos starten →